Compare HYLN & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HYLN | VALN |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | United States | France |
| Employees | 113 | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 587.6M | 582.2M |
| IPO Year | 2019 | 2021 |
| Metric | HYLN | VALN |
|---|---|---|
| Price | $3.37 | $5.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | $7.75 | ★ $12.25 |
| AVG Volume (30 Days) | ★ 1.4M | 21.3K |
| Earning Date | 11-10-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,475,000.00 | N/A |
| Revenue This Year | $334.53 | N/A |
| Revenue Next Year | $139.40 | $87.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 130.28 | N/A |
| 52 Week Low | $1.56 | $4.75 |
| 52 Week High | $8.49 | $12.18 |
| Indicator | HYLN | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 45.54 | 47.99 |
| Support Level | $3.16 | $5.51 |
| Resistance Level | $4.62 | $6.69 |
| Average True Range (ATR) | 0.18 | 0.18 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 47.85 | 63.38 |
Hyliion Holdings Corp designs and develops power generators for stationary and mobile applications and provides R&D service. It provides solutions that enable clean, flexible, and affordable electricity production. The company focuses on delivering distributed power generators that can operate on various fuel sources to future-proof against an ever-changing energy economy. In addition to stationary power solutions, it focuses on mobile applications, including vehicles and marine technologies. Its products and services include: KARNO Power Modules which is a modular, fully enclosed, fuel-agnostic and fully integrated power generating solution.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.